Veterans Health Administration Novel Therapeutics Preparedness Act
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill adds or tightens a compliance mandate provision: 2. Findings Congress finds the following: Emerging therapeutic interventions, including certain psychedelic-assisted therapies under evaluation by the Food and Drug, expands a appropriation, reporting req, compliance mandate provision: 3, and expands a appropriation, reporting req, compliance mandate provision: 7392. It relies on compliance mandates, appropriations, reporting requirements, and product standards. The main policy areas are Healthcare.
Who Benefits and How
The available clause analysis does not identify a specific beneficiary group.
Who Bears the Burden and How
No clear private burden is identified from the available clause analysis; implementing agencies may still take on administrative work.
Key Provisions
- Adds or tightens a compliance mandate provision: 2. Findings Congress finds the following: Emerging therapeutic interventions, including certain psychedelic-assisted therapies under evaluation by the Food and Drug...
- Expands a appropriation, reporting req, compliance mandate provision: 3.
- Expands a appropriation, reporting req, compliance mandate provision: 7392.
- Expands a appropriation, compliance mandate provision: 7393. Clinical Implementation Program for Emerging Therapeutics The Secretary, acting through the Office of Novel Therapeutics, shall establish a Clinical...
- Expands a appropriation, compliance mandate, product standard provision: 7394.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for primary purpose and policy domains.
At a Glance
What This Bill Does
The bill adds or tightens a compliance mandate provision: 2. Findings Congress finds the following: Emerging therapeutic interventions, including certain psychedelic-assisted therapies under evaluation by the Food and Drug, expands a appropriation, reporting req, compliance mandate provision: 3, and expands a appropriation, reporting req, compliance mandate provision: 7392.
Key Policy Areas
Healthcare
Primary Purpose
The bill adds or tightens a compliance mandate provision: 2. Findings Congress finds the following: Emerging therapeutic interventions, including certain psychedelic-assisted therapies under evaluation by the Food and Drug, expands a appropriation, reporting req, compliance mandate provision: 3, and expands a appropriation, reporting req, compliance mandate provision: 7392.
Policy Domains
Sponsors
Legislative Progress
In CommitteeCommittee on Veterans' Affairs. Hearings held.
Read twice and referred to the Committee on Veterans' Affairs.
Introduced in Senate
Mr. Sheehy (for himself, Mr. Gallego, Ms. Duckworth, and Mr. …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_commission"
- → The commission identified in the operative section
- "the_administrator"
- → The Administrator identified in the operative section
- "secretary_of_defense"
- → Secretary of Defense
- "secretary_of_health_and_human_services"
- → Secretary of Health and Human Services
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology